IL257035A - Combination therapy using acamprosate and d-cycloserine - Google Patents
Combination therapy using acamprosate and d-cycloserineInfo
- Publication number
- IL257035A IL257035A IL257035A IL25703518A IL257035A IL 257035 A IL257035 A IL 257035A IL 257035 A IL257035 A IL 257035A IL 25703518 A IL25703518 A IL 25703518A IL 257035 A IL257035 A IL 257035A
- Authority
- IL
- Israel
- Prior art keywords
- acamprosate
- cycloserine
- combination therapy
- therapy
- combination
- Prior art date
Links
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 title 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 title 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 title 1
- 229960004047 acamprosate Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200864P | 2015-08-04 | 2015-08-04 | |
| PCT/US2016/045547 WO2017024129A1 (en) | 2015-08-04 | 2016-08-04 | Combination therapy using acamprosate and d-cycloserine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL257035A true IL257035A (en) | 2018-03-29 |
Family
ID=57944041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257035A IL257035A (en) | 2015-08-04 | 2018-01-21 | Combination therapy using acamprosate and d-cycloserine |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180221315A1 (enExample) |
| EP (1) | EP3331518A4 (enExample) |
| JP (2) | JP2018526345A (enExample) |
| KR (1) | KR20180034442A (enExample) |
| AU (2) | AU2016303610A1 (enExample) |
| CA (1) | CA2993614A1 (enExample) |
| HK (1) | HK1255584A1 (enExample) |
| IL (1) | IL257035A (enExample) |
| SG (1) | SG10201914045QA (enExample) |
| WO (1) | WO2017024129A1 (enExample) |
| ZA (1) | ZA201800558B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016303610A1 (en) * | 2015-08-04 | 2018-02-01 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and D-cycloserine |
| EP3624788A4 (en) | 2017-05-17 | 2021-03-03 | Confluence Pharmaceuticals, LLC | FORMULATIONS OF HOMOTAURIN AND SALT THEREOF |
| KR102608479B1 (ko) | 2017-05-25 | 2023-12-01 | 글리테크 엘엘씨. | Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법 |
| US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
| JP2025069475A (ja) * | 2022-03-08 | 2025-05-01 | ソシウム株式会社 | Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤 |
| EP4702978A1 (en) * | 2023-04-27 | 2026-03-04 | Socium Inc. | Agent for treating or preventing amyotrophic lateral sclerosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU765603C (en) * | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2009004082A2 (en) * | 2007-07-05 | 2009-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticonvulsive pharmaceutical compositions |
| ES2530047T3 (es) * | 2009-02-12 | 2015-02-26 | Indiana University Research And Technology Corporation | Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido |
| US20100216805A1 (en) * | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2013002584A2 (ko) * | 2011-06-28 | 2013-01-03 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| KR102790656B1 (ko) * | 2015-05-04 | 2025-04-02 | 컨플루언스 파마슈티컬스, 엘엘씨 | 아캄프로세이트의 스프링클 제형 |
| AU2016303610A1 (en) * | 2015-08-04 | 2018-02-01 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and D-cycloserine |
-
2016
- 2016-08-04 AU AU2016303610A patent/AU2016303610A1/en not_active Abandoned
- 2016-08-04 JP JP2018504281A patent/JP2018526345A/ja active Pending
- 2016-08-04 KR KR1020187002542A patent/KR20180034442A/ko not_active Ceased
- 2016-08-04 CA CA2993614A patent/CA2993614A1/en not_active Abandoned
- 2016-08-04 WO PCT/US2016/045547 patent/WO2017024129A1/en not_active Ceased
- 2016-08-04 HK HK18114711.9A patent/HK1255584A1/zh unknown
- 2016-08-04 US US15/749,705 patent/US20180221315A1/en not_active Abandoned
- 2016-08-04 EP EP16833870.5A patent/EP3331518A4/en not_active Withdrawn
- 2016-08-04 SG SG10201914045QA patent/SG10201914045QA/en unknown
-
2018
- 2018-01-21 IL IL257035A patent/IL257035A/en unknown
- 2018-01-26 ZA ZA201800558A patent/ZA201800558B/en unknown
-
2020
- 2020-06-02 US US16/890,533 patent/US20200360316A1/en not_active Abandoned
-
2021
- 2021-06-22 JP JP2021103459A patent/JP2021152060A/ja active Pending
-
2022
- 2022-04-01 AU AU2022202218A patent/AU2022202218A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200360316A1 (en) | 2020-11-19 |
| AU2022202218A1 (en) | 2022-04-21 |
| KR20180034442A (ko) | 2018-04-04 |
| JP2021152060A (ja) | 2021-09-30 |
| US20180221315A1 (en) | 2018-08-09 |
| JP2018526345A (ja) | 2018-09-13 |
| WO2017024129A1 (en) | 2017-02-09 |
| SG10201914045QA (en) | 2020-03-30 |
| AU2016303610A1 (en) | 2018-02-01 |
| CA2993614A1 (en) | 2017-02-09 |
| EP3331518A1 (en) | 2018-06-13 |
| EP3331518A4 (en) | 2019-04-03 |
| ZA201800558B (en) | 2019-10-30 |
| HK1255584A1 (zh) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263521A (en) | Combination therapy | |
| SG10201912792YA (en) | Therapeutic compounds and methods | |
| GB201516442D0 (en) | Combination therapy | |
| GB201707153D0 (en) | Therapy | |
| IL265406B (en) | combined treatment | |
| IL257976A (en) | Combined treatment | |
| SG11201707816PA (en) | Patient interface and aspects thereof | |
| GB201708663D0 (en) | Therapy | |
| ZA201800558B (en) | Combination therapy using acamprosate and d-cycloserine | |
| GB201609597D0 (en) | Therapy | |
| ZA201804155B (en) | Combination therapy | |
| GB201604318D0 (en) | Combination therapy | |
| GB201604316D0 (en) | Combination therapy | |
| GB201603653D0 (en) | Combination Therapy | |
| IL265340A (en) | Combination therapy | |
| GB201617470D0 (en) | Novel therapy | |
| GB201609735D0 (en) | Combination therapy | |
| GB201618477D0 (en) | Therapy | |
| GB201615923D0 (en) | Macrophage-based therapy | |
| GB201707945D0 (en) | Cnacer therapy | |
| GB201707183D0 (en) | Macrophage-based therapy | |
| GB201609721D0 (en) | Cobination therapy | |
| GB201609312D0 (en) | Therapy | |
| GB201609322D0 (en) | Therapy | |
| GB201703453D0 (en) | Therapy |